As out-of-pocket costs for neurologic medications rise, people less likely to take them

February 19, 2020

MINNEAPOLIS - As out-of-pocket costs go up for drugs for the neurologic disorders Alzheimer's disease, peripheral neuropathy and Parkinson's disease, people are less likely to take the drugs as often as their doctors prescribed, according to a study funded by the American Academy of Neurology and published in the February 19, 2020, online issue of Neurology®, the medical journal of the American Academy of Neurology.

"These results are concerning, especially as we've seen the cost of prescription drugs continue to rise and an increasing amount of the cost being shifted to patients through out-of-pocket costs," said study author Brian C. Callaghan, MD, MS, of the University of Michigan in Ann Arbor and a Fellow of the American Academy of Neurology. "Of course, if people do not follow their prescriptions correctly, they are less likely to benefit from the drug and see improvements in their condition, possibly leading to complications and higher costs later."

For the study, researchers examined a private insurance claims database for new cases of Alzheimer's disease or other dementia, Parkinson's disease, and peripheral neuropathy over a 15-year period. Peripheral neuropathy is a common condition in which the peripheral nerves become damaged, causing weakness, numbness and pain, typically in the hands and feet. All of these conditions have drugs available that have similar effectiveness and side effects, but different out-of-pocket costs.

For example, the average out-of-pocket cost in 2016 for a 30-day supply of the Alzheimer's drug rivastigmine was $79.30, compared to $3.10 for the drug donepezil. For the peripheral neuropathy drug pregabalin the cost was $65.70, compared to $8.40 for gabapentin. For Parkinson's, the drug pramipexole cost $35.90, compared to $12.40 for the drug ropinirole.

The researchers then looked at how closely the people followed their prescriptions by seeing how many days' worth of the drug were supplied to each person within the first six months.

The study involved 19,820 people with dementia who were taking the study drugs; 52,249 people with neuropathy who were taking the class of drugs called gabapentinoids, which include pregabalin and gabapentin; 5,246 people with neuropathy who were taking the class of drugs called mixed serotonin-norepinephrine reuptake inhibitors (SNRIs), which included duloxetine and venlafaxine; and 3,130 people with Parkinson's who were taking the study drugs.

The study found that increases in out-of-pocket costs by $50 were associated with lower adherence to prescriptions. For Alzheimer's disease, a $50 increase in out-of-pocket costs was associated with a 12-percent decrease in the medication possession ratio, which is the percentage of time a person has access to medication. For example, in 2015, when the cost of the drug donepezil was about $3 for a 30-day supply, people filled their prescriptions about 70 percent of the time; this is compared to the drug rivastigmine, which cost about $100 for a 30-day supply at that time and people filled their prescriptions about 45 percent of the time.

For peripheral neuropathy, a $50 increase in out-of-pocket costs for the gabapentinoid drugs was associated with a 9-percent decrease in the medication possession ratio.

The researchers also found that Asian, black and Latino people had larger drops in medication adherence rates than white people for equivalent increases in out-of-pocket costs.

"New approaches to increase medication adherence for these population groups is critically important to reducing health care disparities," Callaghan said.

Callaghan also noted that people with Alzheimer's disease and neuropathy often have other conditions that require medication, so the effect of out-of-pocket drug costs may be magnified.

"Out-of-pocket costs have risen to the point where systematic changes are needed," said James C. Stevens, MD, FAAN, President of the American Academy of Neurology. "These changes could include legislative action to place a cap on out-of-pocket costs, which the American Academy of Neurology is advocating for in Washington, D.C. Another change could be to provide neurologists with access to information on drugs costs so that when they meet with patients to make treatment decisions, they can help to minimize the financial burden."
A limitation of the study was that researchers were not able to measure how many people never filled their first prescription of a drug, which could be related to out-of-pocket costs. In addition, the study looked only at people with private insurance, so the results may not apply to other populations.

The study was supported by the American Academy of Neurology.

Learn more about brain disorders at, home of the American Academy of Neurology's free patient and caregiver magazine focused on the intersection of neurologic disease and brain health. Follow Brain & Life® on Facebook, Twitter and Instagram.

The American Academy of Neurology is the world's largest association of neurologists and neuroscience professionals, with over 36,000 members. The AAN is dedicated to promoting the highest quality patient-centered neurologic care. A neurologist is a doctor with specialized training in diagnosing, treating and managing disorders of the brain and nervous system such as Alzheimer's disease, stroke, migraine, multiple sclerosis, concussion, Parkinson's disease and epilepsy.

For more information about the American Academy of Neurology, visit or find us on Facebook, Twitter, Instagram, LinkedIn and YouTube.

Media Contacts:

Renee Tessman,, (612) 928-6137
Michelle Uher,, (612) 928-6120

American Academy of Neurology

Related Medication Articles from Brightsurf:

New medication may treat underlying causes of hypertrophic cardiomyopathy
Mavacamten, a new investigational cardiac medication, may improve heart function for people with thickened heart muscle leading to obstructed blood flow through the heart, a condition known as obstructive hypertrophic cardiomyopathy.

Therapy plus medication better than medication alone in bipolar disorder
A review of 39 randomized clinical trials by scientists from UCLA and their colleagues from other institutions has found that combining the use medication with psychoeducational therapy is more effective at preventing a recurrence of illness in people with bipolar disorder than medication alone.

Kids diagnosed with ADHD often don't take medication regularly
Children diagnosed with ADHD inconsistently take their prescribed medication, going without treatment 40 per cent of the time, a new study has found.

Long-term medication for schizophrenia is safe
Researchers at Karolinska Institutet in Sweden and their colleagues in Germany, the USA and Finland have studied the safety of very long-term antipsychotic therapy for schizophrenia.

Which is more effective for treating PTSD: Medication, or psychotherapy?
A systematic review and meta-analysis led by Jeffrey Sonis, MD, MPH, of the University of North Carolina School of Medicine, finds there is insufficient evidence at present to answer that question.

ADHD medication: How much is too much for a hyperactive child?
When children with ADHD don't respond well to Methylphenidate (MPH, also known as Ritalin) doctors often increase the dose.

Pain medication use by children after common surgeries
About 400 caregivers reported pain medication use by children after common surgeries such as hernia, elbow fracture, appendectomy or adenoid removal in this study.

Bringing cancer medication safely to its destination
Treating cancer more selectively and more effectively -- this could be achieved with an innovative technology developed by teams of researchers at the Leibniz-Forschungsinstitut für Molekulare Pharmakologie (FMP) and the Ludwig-Maximilians-Universität München (LMU).

Bullying linked to student's pain medication use
In a school-based survey study of all students in grades 6, 8, and 10 in Iceland, the use of pain medications was significantly higher among bullied students even when controlling for the amount of pain they felt, as well as age, gender, and socioeconomic status.

New medication gives mice bigger muscles
Researchers from Aarhus University, Denmark, have studied a new group of medicinal products which increase the muscle- and bone mass of mice over a few weeks.

Read More: Medication News and Medication Current Events is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to